Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Mass Balance of 14C-labeled AL8326 in Healthy Subjects

NCT07132957 is registered in ClinicalTrials.gov with Advenchen Laboratories Nanjing Ltd. as lead sponsor.

NCT NCT07132957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07132957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Mass Balance of 14C-labeled AL8326 in Healthy Subjects
Lead sponsor
Advenchen Laboratories Nanjing Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 21, 2025
Completion date
May 17, 2025
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer, solid tumors